trial

Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia

NCTId NCT00407277
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 120 (estimated)
Sponsored by Centre for Addiction and Mental Health
Primary completion 2008-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
120 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2007-02
Primary completion
2008-08
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Nicotine patchsmoking cessation group therapy

Sponsors

Centre for Addiction and Mental HealthLead Sponsor
Canadian Psychiatric Research FoundationCollaborator

Investigators

1
Jeff Daskalakis, MD, PhDPrincipal Investigator

Sites

1 total
Toronto, Canada

Facts & assertions

4 sourced
Enrollment
120
Phase
NA
Primary Completion Date
2008-08
Status
COMPLETED
relationships
The graph out of here
drug
Nicotine patch
drug
smoking cessation group therapy
drug
lead_sponsor
Centre for Addiction and Mental Health
company
collaborator
Canadian Psychiatric Research Foundation
company
indication
Smoking
indication
Nicotine Dependence
indication
Schizophreniform Disorders
indication
investigator
Jeff Daskalakis, MD, PhD
person